Molecular basis for the activation of thyrotropin-releasing hormone receptor

Su-Yu Ji1,2,3,4, Ying-Jun Dong1,2,3,4, Li-Nan Chen1, Shao-Kun Zang1,2,3,4, Jiawei Wang5,6, Dan-Dan Shen5, Jia Guo1, Jiao Qin1, Huibing Zhang1, Wei-Wei Wang1, Qingya Shen5, Yan Zhang5,6,7,8, Zhangfa Song5,6,8, and Chunyou Mao5,6,8

Dear Editor,

Thyrotropin-releasing hormone receptor (TRHR), a class A G protein-coupled receptor (GPCR), is a key signal transducer in hypothalamus–pituitary–thyroid axis1. TRHR is mainly expressed in the anterior pituitary where it modulates the synthesis and release of thyroid-stimulating hormone and prolactin via mediating the actions of thyrotropin-releasing hormone (pGlu-His-Pro-NH2 (TRH)). Upon activation, TRHR primarily couples Gq/11 proteins to exert its regulatory roles2. Here, we report the high-resolution cryo-electron microscopy (cryo-EM) structure of the TRH-bound TRHR–Gq signaling complex. Combined with cellular signaling assays, 3D variability analysis and molecular dynamics (MD) simulations, our results reveal the molecular basis of ligand recognition and activation of TRHR.

To improve the expression and stabilize the TRHR–Gq complex, we combined several strategies to assemble the complex, including an engineered construct of human TRHR with a BRIL fused to the N-terminus and the C-terminus truncated at Y348, the widely used dominant-negative Goq chimera (GoqN, hereafter referred to as Goq for brevity) and NanoBiT tethering strategy3,4. The structure of TRHR–Gq complex was determined to a nominal global resolution of 2.7 Å by single-particle cryo-EM, allowing accurate modeling of TRH, receptor residues E13 to N336 with the exception of intracellular loop 3 (ICL3) and most residues of Gq (Fig. 1a; Supplementary Figs. S1–S3 and Table S1).

Compared with recently reported two structures of TRH-bound TRHR–Gq complexes5,6, our higher-resolution reconstruction provides a more accurate template to characterize the peptide recognition and activation of TRHR. Of note, our structure resolved an extended N-terminal region (residues 13–21) of the receptor, which has not been observed in both previously solved structures5,6 (Fig. 1a, b). The N-terminal portion points towards the extracellular loop 2 (ECL2) of the receptor and makes extensive contacts with the residues 171–176 at the tip of the conserved β-hairpin (Fig. 1b). The extreme N-terminus of TRHR (residues 1–12) was not resolved in our cryo-EM map, likely owing to its intrinsic flexibility. However, truncation of the N-terminal twelve residues (residues 1–12; ΔN12) appeared to compromise the activation of TRHR (Fig. 1c; Supplementary Tables S2 and S3). Further deletion of the N-terminal residues that contact ECL2 (residues 1–18; ΔN18) led to a substantial 50% reduction in maximal responses (f\text{max}) of TRH (Fig. 1c; Supplementary Tables S2 and S3).

Nevertheless, our MD simulation analysis indicated that both the ΔN12 and ΔN18 mutants did not jeopardize the binding of the agonist, exhibiting a similar and marginal root mean square deviation (RMSD) value of ~0.9 Å for TRH (Supplementary Fig. S4). These results suggest that the N-terminal portion of TRHR may allosterically regulate the activation of TRHR.

TRH occupies a canonical ligand pocket in the seven-transmembrane (7TM) bundle, with its C-terminal Pro-NH2 located in the receptor core and the N-terminal pGlu pointing towards ECL3 (Fig. 1d). Compared with other class A peptide GPCR complexes solved so far, TRH sits into the 7TM core as deeply as most of the class A peptide agonists,
Fig. 1 Ligand recognition and activation of human TRHR. 

a Cryo-EM structure of the TRH-bound TRHR–Gq complex. The density of TRH is shown. TRHR, slate blue; Gαq, burly wood; Gβ, pale violet red; Gy, light slate gray; scFv16, rosy brown. The resolved N-terminus of TRHR is highlighted in sea green. 

b Interactions between the extended N-terminus and ECL2 of TRHR. 

c Effects of the N-terminal truncations (ΔN12 and ΔN18) on TRH-induced receptor activation. The Gq dissociation signal was detected by NanoBiT assay. 

d Detailed interactions of TRH (orange) with TRHR (slate blue). Hydrogen bonds are depicted as green dashed lines. 

e Effects of mutations in TRH-binding pocket on TRH-induced Gq dissociation signal as indicated by NanoBiT assay. Bars represent differences in calculated TRH potency [pEC50] for representative mutants relative to the wild-type receptor (WT). Data are colored according to the extent of effect. 

f Close structure examination of the non-conserved S113 in the “PIF” motif of TRHR. Replacement of S113 with I3 may form steric hindrance with the adjacent residues R283 and F199. 

g The effect of S113 mutations in TRHR on TRH-induced Gq dissociation signal. Data are shown as means ± SEM from at least three independent experiments performed in technical triplicate. The cell surface expression and E\text{\textsubscript{max}} values were normalized to WT TRHR. nd not determined, ns no significance. P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 by one-way ANOVA followed by Dunnett’s multiple comparisons test, compared with WT.
except for neurotensin and galanin that bind superficially to ligand pocket$^{7,9}$ (Supplementary Fig. S5). However, the tripeptide TRH forms much fewer interactions with the extracellular end of 7TM and ECLs, displaying a smaller interface (522 Å$^2$) with the receptor than that of other peptide agonists (Fig. 1d; Supplementary Fig. S5). Detailed interaction analysis revealed that TRH forms extensive hydrogen-bonding or polar interactions with TRHR, involving the residues in TM3/5/6/7 and ECL2 (T102$^{3.29}$, Y106$^{3.33}$, Y181$^{1.12}$, R185$^{5.32}$, Y192$^{5.39}$, Y282$^{6.51}$, N289$^{6.58}$, R306$^{7.39}$, Y310$^{7.43}$, superscripts refer to Ballesteros–Weinstein numbering$^9$) (Fig. 1d; Supplementary Table S4). Our cellular signaling assay showed that most alanine mutations severely compromised TRH activity (Fig. 1d, e; Supplementary Fig. S6). The S3.40 with the typical I3.40 would cause steric hindrance with the adjacent residues R283$^{6.52}$ or F199$^{5.46}$ of TRHR, whereas the S113$^{3.40}$A mutation with no disruption to the local residue conformations retained the comparable signaling as the wild-type receptor (Fig. 1f, g; Supplementary Tables S2 and S3). Consistently, sequence alignment of TRHR from different species demonstrated that the functional residues S$^{3.40}$ and A$^{3.40}$ but not I$^{3.40}$ are highly preserved in TRHR orthologs (Supplementary Fig. S8). Unlike TRHR, the substitution of T129$^{3.40}$ with I$^{3.40}$ in CCK$_\alpha$R seemed to enhance the hydrophobic interactions with V125$^{3.36}$, L217$^{5.46}$ and F330$^{6.52}$ (Supplementary Fig. S7c). Indeed, our cellular signaling assays showed that mutation of T129$^{3.40}$ with I$^{3.40}$ in CCK$_\alpha$R evidently increased the agonist potency (Supplementary Fig. S7d). These results highlight the commonality and diversity of the activation mechanisms among class A GPCRs.

The TRHR–G$\alpha_q$ interface involves TM2/3/5/6/7, ICL1/2 and helix 8 of the receptor and α5-helix, β1, αN-helix and Gβ of G$\alpha_q$ with a total interface area of 1483 Å$^2$ (Supplementary Fig. S9a, b). Structural comparisons of the reported GPCR–G$\alpha_q$ complexes showed that G$\alpha_q$ inserted into a similar cavity formed by the intracellular ends of TMs and ICLs but rotated within a range of 15° (Supplementary Fig. S9c–e). To get insights into the structural dynamics between TRHR and G$\alpha_q$, we further performed 3D variability analysis using the final particles for 3D reconstruction. 3D variability analysis revealed that the overall conformation of the TRHR–G$\alpha_q$ complex is stable, with only slight motions observed in the N-terminus (~2.5 Å), ECL2 (~3.0 Å) and helix 8 (2.7 Å) of the receptor, the TRH agonist (~0.8 Å) and the coupled G$\alpha_q$ (~1.2 Å) for both components (Supplementary Fig. S10).

In conclusion, we report the high-resolution cryo-EM structure of the TRH-bound TRHR–G$\alpha_q$ complex, which provides molecular insights into TRHR activation. Compared with the recent two related studies$^{5,6}$, our work provides additional structural and functional details. First, our structure resolved an extended N-terminal region (residues 13–21) of TRHR, which may allosterically regulate the receptor activation (Fig. 1a–c). Second, our higher-resolution structure defined a more accurate ligand-binding pose and interactions providing a precise platform for drug discovery (Fig. 1d; Supplementary Fig. S5a).

The resolved TRHR structure adopts a classic active-state conformation of class A peptide GPCRs, highly similar to the reported cholecystokinin A receptor (CCK$_\alpha$R) with a Ca RMSD value < 1 Å for the 7TM bundle$^{10}$ (Supplementary Fig. S7a). Meanwhile, the conserved “micro-switches” (Toggle switch, DRY, NPxxY, PIF motif) that are essential for the activation of class A GPCRs show almost identical conformations between TRHR and CCK$_\alpha$R, suggesting a conserved activation mechanism for TRHR$^{11}$ (Supplementary Fig. S7b). Intriguingly, the conserved I$^{3.40}$ in the P$^{5.50}$I$^{3.33}$F$^{4.64}$ motif of class A GPCRs is replaced by a rare S113$^{3.40}$ in TRHR and a T$^{3.40}$ in CCK$_\alpha$R, respectively (Fig. 1f; Supplementary Fig. S7c). Structural analysis indicated that substitution of S113$^{3.40}$ with the typical I$^{3.40}$ would cause steric hindrance with the adjacent residues R283$^{6.52}$ or F199$^{5.46}$ of TRHR, which might impair the receptor activation (Fig. 1f). As expected, replacement of S113$^{3.40}$ with I$^{3.40}$ markedly compromised the TRH-induced receptor activation, whereas the S113$^{3.40}$A mutation with no disruption to the
Author details
1Department of Biophysics and Department of Pathology of Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China. 2Center for Structural Pharmacology and Therapeutics Development, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. 3Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. 4Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, Zhejiang, China. 5Department of Colorectal Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. 6Key Laboratory of Biological Treatment of Zhejiang Province, Hangzhou, Zhejiang, China. 7MOE Frontier Science Center for Brain Research and Brain-Machine Integration, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. 8Zhejiang Provincial Key Laboratory of Immunity and Inflammatory diseases, Hangzhou, Zhejiang, China.

Author contributions
Y.Z. and C.M. conceived and supervised the whole project; C.M. and S.-Y.J. purified the TRHR–Gq complex and performed cryo-EM map calculation and model building; D.-D.S. evaluated the sample by negative-stain EM; J.G. and J.Q. collected the cryo-EM data; S.-Y.J., Y.-J.D., L.-N.C., and J.W. performed the cellular functional assays; C.M. and S.-K.Z. performed MD simulations; S.-K.Z., H.Z., W.-W.W., Q.S., and Z.S. participated in data analysis; C.M., Y.Z., and Z.S. wrote the manuscript with inputs from all authors.

Data availability
The atomic coordinate and the electron microscopy map of the TRH-bound TRHR–Gq complex have been deposited in the Protein Data Bank (PDB) under accession number 7XW9 and Electron Microscopy Data Bank (EMDB) under accession code EMD-33494, respectively.

Conflict of interest
The authors declare no competing interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41421-022-00477-0.

Received: 26 July 2022 Accepted: 27 September 2022 Published online: 25 October 2022

References
1. Joseph-Bravo, P., Jaimes-Hoy, L., Uribe, R. M. & Charli, J. L. 60 Years of neuroendocrinology: TRH, the first hypophysiotropic releasing hormone isolated: control of the pituitary-thyroid axis. J. Endocrinol. 227, X3 (2015).
2. Hinkle, P. M., Gehret, A. U. & Jones, B. W. Desensitization, trafficking, and resensitization of the pituitary thyrotropin-releasing hormone receptor. Front. Neurosci. 6, 180 (2012).
3. Mobbs, J. I. et al. Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. PLoS Biol. 19, e3001295 (2021).
4. Duan, J. et al. Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy. Nat. Commun. 11, 4121 (2020).
5. Xu, Y. et al. Structural insights into ligand binding and activation of the human thyrotropin-releasing hormone receptor. Cell Res. 32, 855–857 (2022).
6. Yang, F. et al. Structural insights into thyrotropin-releasing hormone receptor activation by an endogenous peptide agonist or its orally administered analogue. Cell Res. 32, 858–861 (2022).
7. Zhang, M. et al. Cryo-EM structure of an activated GPCR-G protein complex in lipid nanodiscs. Nat. Struct. Mol. Biol. 28, 258–267 (2021).
8. Duan, J. et al. Molecular basis for allosteric agonism and G protein subtype selectivity of galanin receptors. Nat. Commun. 13, 1364 (2022).
9. Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In Methods in Neurosciences. Vol. 25 (ed Seattle, S. C.) 366–428 (Academic Press, 1995).
10. Liu, Q. et al. Ligand recognition and G-protein coupling selectivity of cholecystokinin A receptor. Nat. Chem. Biol. 17, 1238–1244 (2021).
11. Zhou, Q. et al. Common activation mechanism of class A GPCRs. Elife 8, e50279 (2019).